Esranur Aydın: A remarkable success in treating a heavily pretreated metastatic CRC patient
Esranur Aydın, Clinical Cancer Molecular Biologist at Medicana Health Group, shared on LinkedIn:
“Publication Allert from our Precision Oncology Center!
Our latest case report in Frontiers in Oncology showcases a remarkable success in treating a heavily pretreated metastatic CRC patient. With a personalized approach combining dual immunotherapy and sorafenib, we achieved a stunning molecular and radiological complete response.
This case underscores the importance of uncovering and addressing uncommon genetic alterations such as FLT3 amplification, which proved pivotal in overcoming treatment resistance. It highlights the critical role of comprehensive genomic profiling (CGP) in guiding personalized treatment strategies, alongside the integration of minimal residual disease (MRD) testing for early treatment response assessment.
Precision oncology is a journey of continual learning and adaptation. By integrating CGP and MRD testing, we swiftly adjusted treatments, leading to improved outcomes and personalized care.
This paper contributes valuable insights to oncology, advancing cancer treatment and reshaping patient care practices worldwide.
A heartfelt shout-out to my incredible team members Ünal Metin Tokat, Ashkan Adibi, Eylul Ozgu, Şevval Nur Bilgiç, and our mentor Prof. Dr. Mutlu Demiray whose expertise and unwavering dedication made this achievement possible!
Read the full paper here.
Stay tuned for more updates as we continue to push the boundaries of precision oncology.”
Source: Esranur Aydın/LinkedIn